Related NEWS: RGBP
3/23/17
Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis.
Analogues Have Been Synthesized for Lead Compounds and are Complete, now the Optimization Process is set to Begin Utilizing NR2F6 Protein Molecules
Regen BioPharma Inc. (OTCQB: RGBP), has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv Inc., for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen's patented screening methodology and unique chemical libraries.
ChemDiv Inc., a fully integrated target-to-clinic contract research organization, which is conducting the compound optimization studies for Regen BioPharma, has reported that they have synthesized more than 30 analogues of our initial small molecules and will begin screening them for activity in the coming weeks. Additionally, purified protein that will be used in these studies has been manufactured and received by the Company. Now that this crucial first phase has been completed, the Company can move forward with ChemDiv on the actual optimization process, which involves introducing the synthesized compound analogues to the special NR2F6 protein molecule and cellular systems.
The NR2F6 nuclear receptor has been identified as a potentially significant immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6, in an effort to unleash the cancer-killing potential of a patient's own immune system, as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as rheumatoid arthritis and other autoimmune diseases.
"The optimization process of small molecule development is iterative. It requires a series of compounds to be synthesized and their activity to be understood. By doing this repeatedly and learning about the relationship between structure and activity, optimized compounds are generated," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "We are on track and on schedule. The next two months will be very important as we define the key portions of the structures that relate to activity in the protein molecule."
"This is an extremely exciting time for Regen as we are moving the company dynamically forward. The ChemDiv studies are the gateway to potentially strong relationships, with one or more large pharmaceutical companies that have already express interest in our NR2F6 small molecule therapeutic models for treating cancer and arthritis immunologically. ChemDiv, Inc. is an elite contract research organization and we are enthusiastic about their involvement with our small molecule drug development program," stated David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. "Their professionalism and deep knowledge of this space makes it easy for us to oversee this process and allows us to strategically plan next steps."
One of these days the op to get into RGBP and ENTB cheap will be over. Looking forward to that. IMO. GL.
